Bill > HR1794

This bill establishes an Abraham Accords Office within the Food and Drug Administration (FDA) to enhance regulatory cooperation with countries that have signed the Abraham Accords, a diplomatic agreement normalizing relations with Israel. The new office will be located in an Abraham Accords country and will be established within two years of the bill's enactment. Its primary responsibilities include providing technical assistance to regulatory partners in these countries, helping to strengthen and converge regulatory oversight of medical products and manufacturing practices, and facilitating interactions between the FDA and interested parties in these countries. The office will share information about U.S. regulatory pathways and gather feedback on research, development, and manufacturing of regulated products. Within three years of enactment, the Secretary of Health and Human Services must submit a report to Congress evaluating the office's progress, including details on regulatory conformance, interactions facilitated, technical assistance provided, and recommendations for future coordination. The bill explicitly states that no actions taken by the office should be inconsistent with national security recommendations, and it defines an "Abraham Accords country" as one identified by the State Department as having signed the Abraham Accords Declaration.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/1794/all-info